Vor Biopharma Inc expected to post a loss of 50 cents a share - Earnings Preview

Vor Biopharma

19/03/2024 11:10

* Vor Biopharma Inc  VOR.OQ   VOR.O  is expected to show no
change
in quarterly revenue when it reports  results on March 21
(estimated) for the period ending December 31 2023
    * 
    * ​LSEG's mean analyst estimate for Vor Biopharma Inc is for
a
loss of 50 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Vor
Biopharma Inc
is $16.25​, above​ its last closing price of $1.92. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.47       -0.47      -0.49     Missed  -4.6
 Jun. 30 2023  -0.44       -0.43      -0.45     Missed  -4.1
 Mar. 31 2023  -0.39       -0.38      -0.43     Missed  -12.2​
 Dec. 31 2022  -0.47       -0.60      -0.52     Beat    13.7
 ​​Sep.        -0.60       -0.61      -0.63     Missed  -3.7
 30 2022                                                
 Jun. 30 2022  -0.66       -0.66      -0.58     Beat    11.9​
 Mar. 31 2022  -0.52       -0.51      -0.61     Missed  -18.9
 Dec. 31 2021  -0.52       -0.57      -0.48     Beat    15.2
 This summary was machine generated March 19 at 11:09 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)